8月21日，康方生物盘中下跌3.41%，报90.7港元，成交额4.24亿港元。
消息面上，公司前一交易日随港股创新药板块集体走强而大涨超9%，当日板块内中国生物制药涨超20%、石药集团涨超16%，康方生物涨超11%。短期急速拉升后获利资金再度兑现离场。回溯来看，自8月12日核心产品依沃西第三适应症（一线鳞状非小细胞肺癌）获批落地以来，股价持续呈现"利好兑现—回吐—反弹—再回吐"的震荡格局，前期连续8日上涨积累的获利盘尚未完全消化。当日生物科技板块表现分化，百济神州跌1.58%，康希诺生物跌11.79%，板块整体承压。公司将于8月27日发布中期业绩，市场对依沃西放量节奏的关注度持续升温。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.